Glomerular Hyperfiltration Raises Cardiovascular Risk in Type 2 Diabetes, Study Recommends Early Screening
South Korea: A study of over 1.9 million patients with type 2 diabetes (T2D) found that glomerular hyperfiltration (GHF) was associated with an increased risk of cardiovascular disease (CVD), particularly myocardial infarction (HR = 1.06) and heart failure (HR = 1.17).
"Patients with GHF (eGFR above the 95th percentile) had a 13% higher risk of CVD compared to those with moderate kidney function (eGFR between the 40th and 60th percentiles). GHF had the most significant impact on patients under 40 years of age," the researchers reported in the Clinical Journal of the American Society of Nephrology.
Seung Min Chung, Division of Endocrinology and Metabolism, Department of Internal Medicine, Yeungnam University College of Medicine, Daegu, Republic of Korea, and colleagues aimed to explore the effects of glomerular hyperfiltration on cardiovascular disease risk in patients with type 2 diabetes mellitus (T2DM).
For this purpose, the researchers conducted a retrospective cohort study using data from 1,952,053 patients with type 2 diabetes mellitus, sourced from the Korean National Health Insurance Service database between 2015 and 2016. Based on age- and sex-specific estimated glomerular filtration rate (eGFR) percentiles, patients were classified into five groups: <5 (low filtration), 5–40, 40–60, 60–95, and >95 (GHF). The study followed patients with incident cardiovascular disease (CVD), including myocardial infarction (MI), stroke, and hospitalization for heart failure (HF), until December 2022.
Key Findings:
- CVD occurred in 214,111 patients (11%) in the study.
- The incidence rates for cardiovascular events were 36.1, 20.8, 18.3, 18.7, and 19.3 per 1000 person-years for the various eGFR groups.
- Both low filtration (HR = 1.56) and GHF (HR = 1.13) were linked to higher CVD risk compared to the eGFR 40–60 percentile group, displaying an inverted J-shaped relationship.
- GHF was associated with an increased risk of myocardial infarction (HR = 1.06), heart failure (HR = 1.17), and stroke.
- eGFR levels were associated with CVD risk across different subgroups, including age, sex, obesity, hypertension, and dyslipidemia.
- The impact of GHF on CVD risk appeared more pronounced in younger patients, with HRs of 1.30, 1.17, and 1.05 for those aged <40, 40–60, and ≥65 years, respectively.
This research emphasizes the need for greater awareness of the relationship between kidney health and cardiovascular outcomes in patients with diabetes. Given the growing global burden of T2DM and its associated complications, understanding how GHF contributes to the development of CVD could have important implications for patient management and treatment strategies.
As the study points out, early intervention for GHF in patients with T2DM could potentially reduce the incidence of cardiovascular events, improving long-term health outcomes for this at-risk population. However, further studies are needed to better understand the mechanisms behind GHF and its impact on cardiovascular health, as well as to evaluate the effectiveness of early screening and intervention strategies.
Reference:
Chung, Seung Min1; Jung, Inha2; Lee, Da Young2; Park, So Young2; Yu, Ji Hee2; Moon, Jun Sung1; Seo, Ji A2; Han, Kyung-do3,a; Kim, Nan Hee2,a. Effect of Glomerular Hyperfiltration on Incident Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. Clinical Journal of the American Society of Nephrology ():10.2215/CJN.0000000618, January 09, 2025. | DOI: 10.2215/CJN.0000000618
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.